Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 10, 2024
Lead Product(s) : Degludec
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 12, 2022
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 05, 2019
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 12, 2019
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 09, 2018
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 27, 2018
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Tresiba
Product Type : Hormone
Upfront Cash : Inapplicable
September 13, 2018
Lead Product(s) : Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable